A unit of Fosun International (HKG:0656) agreed to purchase 14,940,694 unlisted shares in Shanghai Henlius Biotech (HKG:2696) from HenLink for a little over HK$367.5 million, a Monday filing with the Hong Kong bourse said.
Shanghai Fosun Pharmaceutical Industrial Development will purchase the shares at HK$24.60 apiece.
The buyer had, in two previous transactions this month, acquired a total of 6,093,619 shares in pharmaceutical firm Henlius Biotech.
Following the completion of all three transactions, conglomerate Fosun International will hold 63.43% of Henlius Biotech's total issued share capital.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。